These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 20222996)
1. Genetic and preventive services for hereditary breast and ovarian cancer in the czech republic. Foretova L; Petrakova K; Palacova M; Kalabova R; Navratilova M; Lukesova M; Vasickova P; Machackova E; Kleibl Z; Pohlreich P Hered Cancer Clin Pract; 2006 Nov; 4(1):3-6. PubMed ID: 20222996 [TBL] [Abstract][Full Text] [Related]
2. Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience. Foretova L; Petrakova K; Palacova M; Kalabova R; Svoboda M; Navratilova M; Schneiderova M; Bolcak K; Krejci E; Drazan L; Mikova M; Hazova J; Vasickova P; Machackova E Klin Onkol; 2010; 23(6):388-400. PubMed ID: 21348412 [TBL] [Abstract][Full Text] [Related]
3. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families. Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759 [TBL] [Abstract][Full Text] [Related]
4. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants. Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081 [TBL] [Abstract][Full Text] [Related]
6. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118 [TBL] [Abstract][Full Text] [Related]
7. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia. Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518 [TBL] [Abstract][Full Text] [Related]
8. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
9. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
10. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778 [TBL] [Abstract][Full Text] [Related]
11. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population. Górski B Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018 [TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Foretova L; Machackova E; Navratilova M; Pavlu H; Hruba M; Lukesova M; Valik D Hum Mutat; 2004 Apr; 23(4):397-8. PubMed ID: 15024741 [TBL] [Abstract][Full Text] [Related]
13. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients. Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021 [TBL] [Abstract][Full Text] [Related]
14. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer. Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591 [TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management. Marchina E; Fontana MG; Speziani M; Salvi A; Ricca G; Di Lorenzo D; Gervasi M; Caimi L; Barlati S Oncol Rep; 2010 Dec; 24(6):1661-7. PubMed ID: 21042765 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017 [TBL] [Abstract][Full Text] [Related]
17. Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster. Nippert I; Schlegelberger B; Community Genet; 2003; 6(4):249-58. PubMed ID: 15331871 [TBL] [Abstract][Full Text] [Related]
18. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene. Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348 [TBL] [Abstract][Full Text] [Related]
19. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer. Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076 [TBL] [Abstract][Full Text] [Related]